ZHEJIANG YONGTAI CHIRAL MEDICINE TECHNOLOGY CO LTD

Overview

ZHEJIANG YONGTAI CHIRAL MEDICINE TECHNOLOGY CO LTD is an active pharmaceutical ingredient (API) supplier with 8 active FDA Type II Drug Master Files, covering CARBIDOPA; CRUDE CARBIDOPA; GABAPENTIN; LEVODOPA; METHYLDOPA; SITAGLIPTIN BASE.

API / Drug Master Files

ZHEJIANG YONGTAI CHIRAL MEDICINE TECHNOLOGY CO LTD holds 8 active (8 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• METHYLDOPAActive2025-12-05
• SITAGLIPTIN BASE (PROCESS B-1)Active2025-12-02
• SITAGLIPTIN PHOSPHATE MONOHYDRATEActive2025-06-13
• SITAGLIPTIN BASEActive2025-03-20
• LEVODOPAActive2024-12-01
• CRUDE CARBIDOPAActive2023-12-19
• CARBIDOPAActive2023-11-17
• GABAPENTINActive2022-10-31

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to ZHEJIANG YONGTAI CHIRAL MEDICINE TECHNOLOGY CO LTD in our records. PharmaTek screens the full directory against live FDA enforcement data.